Avalo Therapeutics Inc expected to post a loss of 73 cents a share - Earnings Preview

Avalo Therapeutics

24/02/2023 18:57

* Avalo Therapeutics Inc  AVTX.OQ   AVTX.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
28 (estimated). 
    * The Rockville Maryland-based  company is expected to
report  a
1,548.7% increase in revenue to $3.611 million from $219
thousand a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Avalo Therapeutics
Inc is
for a loss of 73 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $10​, above​ its last closing price
of $3.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -1.09       -1.09      0.34      Beat    131.1
 Jun. 30 2022  -1.76       -1.77      -1.38     Beat    22
 Mar. 31 2022  -1.55       -1.60      -2.40     Missed  -50​
 Dec. 31 2021  -1.75       -1.90      -1.92     Missed  -1.3
 ​​Sep.        -2.19       -2.16      -2.04     Beat    5.6
 30 2021                                                
 Jun. 30 2021  -2.09       -2.04      -2.16     Missed  -5.9​
 Mar. 31 2021  -2.47       -2.32      -3.84     Missed  -65.5
 Dec. 31 2020  -1.80       -1.80      -2.16     Missed  -20
 This summary was machine generated February 24 at 18:57 GMT. 
All figures in US dollars  unless otherwise stated